$ANPC News

Last published 3y ago

3y agoANPCFresh2 Group Ltd. Announces Nasdaq Ticker Symbol Change from 'ANPC' to 'FRES'PR NewswireTicker symbol change effective at the market open May 22, 2023 NEW YORK, May 19, 2023 /PRNewswire/ -- Fresh2 Group Ltd., formerly AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC), a company with operations in the
3y agoANPCFresh2 Files Annual Report on Form 20-F for Fiscal Year 2022PR NewswireNEW YORK, May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd., "Fresh2," the "Company" or "we") (NASDAQ:ANPC), a company with operations in the United
3y agoANPCFresh2 Reports Fiscal Year 2022 Annual Financial ResultsPR NewswireNEW YORK, May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd. ,"Fresh2," the "Company" or "we") (NASDAQ:ANPC), a company with operations in the United
3y agoANPCFresh2 Reports First Quarter of Fiscal Year 2023 Financial ResultsPR NewswireNEW YORK, May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd., "Fresh2," the "Company" or "we") (NASDAQ:ANPC), a company with operations in the United
3y agoANPCUnivest Securities, LLC Announces Closing of $3.0 Million Registered Direct Offering for its Client AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC)GlobeNewswireNew York, April 06, 2023 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the
3y agoANPCAnPac Bio-Medical Science Announces Closing of $3.0 Million Registered Direct OfferingPR NewswireNEW YORK, April 6, 2023 /PRNewswire/-- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection
3y agoANPCAnPac Bio-Medical Science Enters into Asset Purchase Agreement with Easy Hundred Inc.PR NewswireNEW YORK, April 3, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection
3y agoANPCAnPac Bio-Medical Science Announces Pricing of $3.0 Million Registered Direct OfferingGlobeNewswireNew York, NY, March 31, 2023 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and
3y agoANPCAnPac Bio-Medical Science Granted Continued Listing by NASDAQ Hearing Panel, Subject to Meeting the Equity Rule on or before July 12, 2023PR NewswireNEW YORK, March 23, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection
3y agoANPCAnPac Bio Announces Receipt of the First Payment from a Malaysia Customer On a Signed US$1.5 Million Cancer Detection Equipment Purchase ContractPR NewswireNEW YORK, March 7, 2023 /PRNewswire/ – AnPac Bio-Medical Science Co., Ltd.
3y agoANPCAnPac Bio-Medical Science Announces US$5 Million Private PlacementPR NewswireNEW YORK, March 6, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) ("AnPac Bio," the "Company" or "we"), a company with operations in the United States and China focused on
3y agoANPCAnPac Bio Announces Positive Results from its Multi-Year and Multi-Cancer Test Follow-Up StudyPR NewswireNEW YORK, Feb. 22, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a company with operations in the United States and China focused on early
3y agoANPCAnPac Bio-Medical Science Acquires GISN (HK) LIMITED, a Technical Solution and Outsourcing Consulting Services ProviderPR NewswireNEW YORK, Feb. 15, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection
3y agoANPCAnPac Bio-Medical Science Enters into Definitive Agreement to Make Another Acquisition to Significantly Expand Scope of Business in the U.S.PR NewswireNEW YORK, Feb. 13, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ:ANPC), a company with operations in the United States and China announced that on February 12, 2023, the
3y agoANPCAnPac Bio-Medical Science Enters into Definitive Agreement to Acquire Fresh2 Ecommerce Inc, a B2B Asian Food E-commerce PlatformPR NewswireTransaction expected to fuel the Company's growth in the U.S. food market NEW YORK, Feb. 9, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ:ANPC), a company with operations in
3y agoANPCAnPac Bio-Medical Science Announces Signing of US$5.2 Million of Definitive Investment AgreementsGlobeNewswireNew York, NY, Jan. 25, 2023 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ:ANPC), a biotechnology company with operations in the United States and China focused on early cancer
3y agoANPCAnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request A HearingGlobeNewswireNew York, NY, Jan. 20, 2023 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (Nasdaq: ANPC), a biotechnology company with operations in the United States and China focused on early cancer
3y agoANPCAnPac Bio Reports 48.8% Decrease in Net Loss in First Half of 2022GlobeNewswirePHILADELPHIA, Dec. 19, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (NASDAQ:ANPC), a biotechnology company with operations in China and the United States, announced
3y agoANPCAnPac Announces Strategic Initiative to Establish A Wholly-Owned Subsidiary for US Food MarketGlobeNewswirePHILADELPHIA, Dec. 05, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) ("AnPac Bio" or the "Company"), a biotechnology company with operations in the United States and China focused on early
3y agoANPCAnPac Announces the Plan of US$5,000,000 Private PlacementGlobeNewswirePHILADELPHIA, Dec. 05, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) ("AnPac Bio" or the "Company"), a biotechnology company with operations in the United States and China focused on early
3y agoANPCAnPac Announces Regaining Compliance with Nasdaq Listing RequirementGlobeNewswirePHILADELPHIA, Nov. 30, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) ("AnPac Bio" or the "Company"), a biotechnology company with operations in the United States and China focused on early
4y agoANPCAnPac Bio Announces Changes to the Board of DirectorsGlobeNewswirePHILADELPHIA, Nov. 10, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) ("AnPac Bio" or the "Company"), a biotechnology company with operations in the United States and China focused on early
4y agoANPCAnPac Bio Granted Continued Listing by NASDAQ Hearing Panel, Subject to Meeting $1 Bid Price Compliance Rule On or Before Nov. 23, 2022GlobeNewswirePHILADELPHIA, Nov. 04, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early
4y agoANPCAnPac Bio Announces Plan to Implement ADS Ratio ChangeGlobeNewswirePHILADELPHIA, Oct. 18, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) ("AnPac Bio" or the "Company"), a biotechnology company with operations in the United States and China focused on early
4y agoANPC ATHM MFH OCFTAnPac Bio Announces Board and Management ChangesGlobeNewswirePHILADELPHIA, Oct. 03, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) ("AnPac Bio" or the "Company"), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, to
4y agoANPCAnPac Bio and New Investor Group Sign Equity Investment Totaling $3.67 MillionGlobeNewswirePHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, a
4y agoANPCAnPac Bio Appeals NASDAQ Delisting Notice; Hearing Granted and Scheduled for October 20, 2022GlobeNewswirePHILADELPHIA, Sept. 19, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, an
4y agoANPCAnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to AppealGlobeNewswirePHILADELPHIA, Sept. 12, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, an
4y agoANPCAnPac Bio Announces Appointment of New Directors and Co-Chief Executive OfficerGlobeNewswirePHILADELPHIA, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, ann
4y agoANPCAnPac Bio Approved Written Resolutions of a Majority of the Members Addressing the Removal of Directors and Officers, Re-designation of Officers, and Change of Members of the CommitteesGlobeNewswirePHILADELPHIA, July 18, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, ann
4y agoANPCAnPac Bio Regains Compliance with Requirements to Remain Listed on Nasdaq Capital MarketGlobeNewswirePHILADELPHIA, June 10, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, ann
4y agoANPCAnPac Bio Reports 49.1% Decrease in Net Loss in First Quarter of Fiscal 2022GlobeNewswirePHILADELPHIA, May 31, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (NASDAQ:ANPC), a biotechnology company with operations in China and the United States, announced today its unaudited financial resul
4y agoANPCAnPac Bio Reports Fiscal Year 2021 Annual Financial ResultsGlobeNewswirePHILADELPHIA, May 16, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (NASDAQ:ANPC), a biotechnology company with operations in China and the United States, announced today its annual financial results
4y agoANPCAnPac Bio Regains Compliance with Market-Value-Of-Publicly Held Shares Requirement upon Transfer to The Nasdaq Capital MarketGlobeNewswirePHILADELPHIA, May 11, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, anno
4y agoANPCNasdaq Hearing Panel Grants AnPac Bio's Request to Transfer Securities from The Nasdaq Global Market to The Nasdaq Capital MarketGlobeNewswirePHILADELPHIA, May 06, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, anno
4y agoANPCAnPac Bio and New Investor Sign Equity Investment Totaling $15 MillionGlobeNewswirePHILADELPHIA, April 11, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, an
4y agoANPCAnPac Bio Appoints Dr. Aidong Chen as New Chief Executive Officer and Chairman of the Board and Miss Sheng Liu as a New Board MemberGlobeNewswirePHILADELPHIA, April 08, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, an
4y agoANPCAnPac Bio Filed Request for a Hearing Regarding Continued Listing on NASDAQ, The Hearing was Granted and scheduled for Late AprilGlobeNewswirePHILADELPHIA, April 04, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, an
4y agoANPCAnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request HearingGlobeNewswirePHILADELPHIA, March 26, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, an
4y agoANPCAnPac Bio-Medical Sciences Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price RequirementGlobeNewswirePHILADELPHIA, March 11, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, an
4y agoANPCAnPac Bio's Bio-Chip Subsidiary, Changwei System Technology Co., Ltd., Receives Independent Valuation and Approval from the Board to Explore Strategic AlternativesGlobeNewswirePHILADELPHIA, March 03, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, an
4y agoANPCAnPac Bio Files CDA Device for Breakthrough Medical Device Designation Request with the FDAGlobeNewswirePHILADELPHIA, Feb. 03, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, ann
4y agoANPCLeading US Market Analysis and Research Firm Ranked AnPac Bio Globally Number One in Multi-Cancer Screening and Detection Test VolumeGlobeNewswirePHILADELPHIA, Jan. 25, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, ann
4y agoANPCAnPac Bio Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares DeficiencyGlobeNewswirePHILADELPHIA, Jan. 24, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (NASDAQ:ANPC), a biotechnology company with operations in the United States and China, announced today that it has received a writt
4y agoANPCAnPac Bio Class III Medical Device Passes Extensive NMPA Registration Tests and Will Start Clinical Trial in Q1, 2022GlobeNewswirePHILADELPHIA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a US and China-based biotechnology company focused on early cancer screening and detection, announced today that on Decembe
4y agoANPCTechnical Paper on AnPac Bio Novel CDA Cancer Detection Technology Published by Peer-Reviewed International Medical JournalGlobeNewswirePHILADELPHIA, Dec. 10, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (NASDAQ:ANPC), a biotechnology company with operations in China and the United States, announced today its joint technical paper on
4y agoANPCAnPac Bio Reports Nine Months Ended September 30, 2021, Same Period Achieved Record Revenue Increased By 55.3% While Non-GAAP Net Loss Reduced by 6.8%GlobeNewswirePHILADELPHIA, Nov. 26, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (NASDAQ:ANPC), a biotechnology company with operations in China and the United States, announced today its unaudited financial resu
5y agoANPCAnPac Bio Announces Pricing of Approximately $2.9 Million Underwritten Public Offering of American Depositary SharesGlobeNewswirePHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC, the "Company"))), a biotechnology company with operations in China and the United States focusing on early cancer screening and detection, today announced
5y agoANPCAnPac Bio Commences Proposed Public Offering of American Depositary SharesGlobeNewswireSUNRISE, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC, the "Company"))), a biotechnology company with operations in China and the United States focusing on early cancer screening and detection, today announce
5y agoAAZZF ABIO ACOGF ACST+81Investor Summit Group Provides Update on Upcoming Q4 Virtual SummitGlobeNewswireNEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- The Investor Summit Group, widely recognized for its reputation as the host of North America's largest independent investor conferences, will be hosting the upcoming Q4 Virtual Summit on November 16-17. The e